ArticleFrontiers in allergy2025
Polymerised mite allergoids with glutaraldehyde reduce proteolytic activity and enhance the stability of allergen mixtures: a proof of concept with grass mixtures.
Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Potent IgE-Mediated Allergenic Reduction in Human Serum by Casein-Polyphenol Conjugates Makes Personalized Oral Immunotherapy Credible.ACS food science & technology · 2026Article
- The Spanish REAL project: expert allergist guidance on allergen immunotherapy based on mixtures from different allergenic sources.Frontiers in allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polysensitized patients require allergen immunotherapy (AIT) targeting multiple allergens. However, combining allergen extracts can lead to instability and reduced efficacy particularly due to the high proteolytic activity of house dust mite (HDM) allergens. While is known that glutaraldehyde cross-linking may reduce enzymatic activity, its ability to stabilize multi-allergen formulations and protect key allergens from degradation remains unexplored. Objective: To evaluate the impact of glutaraldehyde polymerization on the stability and immunogenicity of HDM and grass pollen allergen formulations, addressing proteolytic activity challenges in multi-allergen vaccines. Methods: Stability was assessed over 24 months through protein quantification and antigenic activity assays. Proteolytic activity of HDM-containing extracts was measured using Azocoll, and peptide substrate-based enzymatic assays. Grass pollen allergen degradation was evaluated by SDS-PAGE, immunoblotting, and ELISA Immunogenicity was assessed in mice immunized with grass allergoids alone or in combination with glutaraldehyde-polymerised HDM, measuring IgG responses, splenocyte proliferation, and IL-10 production. Results: Glutaraldehyde polymerization significantly reduced HDM proteolytic activity ( Conclusions: Polymerised allergen extracts address the challenges of proteolytic degradation in multi-allergen formulations, offering stable, immunogenic vaccines that maintain efficacy and provide a reliable treatment option for polyallergic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.